Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 1, 2000, Pages 27-34

  Braybrooke, Jeremy P ^a   Vallis, Katherine A ^a,c   Houlbrook, Susan ^a   Rockett, Helen ^a   Ellmén, Juha ^b   Anttila, Markku ^b   Ganesan, Trivadi S ^a   Harris, Adrian L ^a   Talbot, Denis C ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ORION CORPORATION   (Finland)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Multidrug resistance; P glycoprotein; Toremifene

Indexed keywords

TOREMIFENE; VINBLASTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033935351     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002809900085     Document Type: Article

References (31)

1. 1. Anttila M, Valavaara R, Kivinen S, Maenpaa J (1990) Pharmacokinetics of toremifene. J Steroid Biochem 36: 249
2. 2. Anttila M, Laakso S, Nylanden P, Sotaniemi EA (1995) Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther 57: 628
3. 3. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH (1986) Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544
4. 4. Bishop J, Murray R, Webster L, Pitt P, Stokes K, Fennessy A, Olver I, Leber G (1992) Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 30: 174
5. 5. Bloom HJ (1971) Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. Br J Cancer 25: 250
6. 6. Chatterjee M, Harris AL (1990) Enhancement of Adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adr, by toremifene and its modulation by alpha-1-acid glycoprotein. Eur J Cancer 26: 432
7. 7. DeGregorio MW, Ford JM, Benz CC, Wiebe VJ (1989) Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7: 1359
8. 8. Fojo AT, Shen DW, Mickley LA, Pastan I, Gottesman MM (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. J Clin Oncol 5: 1922
9. 9. Fossa SD, Droz JP, Pavone-Macaluso MM, Debruyne FJ, Vermeylen K, Sylvester R (1992a) Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer 28A: 878
10. 10. Fossa SD, Martinelli G, Otto U, Schneider G, Wander H, Oberling F, Bauer HW, Achtnicht U, Holdener EE (1992b) Recombinant interferon-α2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multicenter phase III study. Ann Oncol 3: 301
11. 11. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, et al (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116
12. 12. Hamm JT (1997) Phase I and II studies of toremifene. Oncology 11: 19
13. 13. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, et al (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556
14. 14. Hrushesky WJ, Murphy GP (1974) Evaluation of chemotherapeutic agents in a new murine renal carcinoma model. J Natl Cancer Inst 52: 1117
15. 15. Kangas L (1990) Biochemical and pharmacological effects of toremifene metabolites. Cancer Chemother Pharmacol 27: 8
16. 16. Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J (1993a) Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 67: 1189
17. 17. Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J (1993b) Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur J Cancer 29A: 1152
18. 18. Kohler PC, Hamm JT, Wiebe VJ, DeGregorio MW, Shemano I, Tormey DC (1990) Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res Treat 16: S19
19. 19. Kremer JM, Wilting J, Janssen LH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40: 1
20. 20. Leyland-Jones B, Dalton W, Fisher GA, Sikic BI (1993) Reversal of multidrug resistance to cancer chemotherapy. Cancer 72: 3484
21. 21. Liippo K, Ellmen J, Vanttinen E, Anttila M (1997) Toremifene concentration and multidrug resistance in lung tumors. Cancer Chemother Pharmacol 39: 212
22. 22. Maenpaa J, Sipila P, Kangas L, Karnani P, Gronroos M (1992) Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol Oncol 46: 292
23. 23. Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353: 14
24. 24. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay F, Powell J (eds) (1992) Cancer incidence in five continents, vol. 6. IARC Scientific Publication No. 120. IARC, Lyon
25. 25. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622
26. 26. Sipila H, Nanto V, Kangas L, Anttila M, Halme T (1988) Binding of toremifene to human serum proteins. Pharmacol Toxicol 63: 62
27. 27. Stuart NS, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J (1992) High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br J Cancer 66: 833
28. 28. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW (1990) Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 25: 247
29. 29. Wiebe V, Koester S, Lindberg M, Emshoff V, Baker J, Wurz G, DeGregorio M (1992) Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells. Invest New Drugs 10: 63
30. 30. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS (1996) Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2: 7
31. 31. Wurz GT, Emshoff VD, DeGregorio MW, Wiebe VJ (1993) Targeting chemosensitizing doses of toremifene based on protein binding. Cancer Chemother Pharmacol 31: 412